Additional Information

Score Description

The European Treatment and Outcome Study (EUTOS) is a prognostic score for chronic phase chronic myeloid leukemia at the time of diagnosis and before starting treatment; derived from multivariate analysis of response of 2060 patients treated – in comparison to the Hasford and Sokal score – with imatinib for CML between 2002 and 2006. The score is able to predict the probability of achieving a complete cytogenetic response (CCgR) within 18 months after the start of therapy.


Low-risk ≤ 87
High-risk > 87
EUTOS Score = (7 × basophils) + (4 × spleen size) where the spleen was measured in centimeters below the costal margin and blood basophils as a percentage at baseline.

Further Reading

Hasford J et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-9.